Jesus Jimenez is a Cardiology physician. ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Cardiology, Ste 8b
Saint Louis, MO 631101032
Telephone
314-362-1291Provider last certified this registry record 10 Sept 2021.
Clinical trials
- Effect of a HIIT Program on Quality of Life, Executive Functions, and IGF-1 Response in Sedentary Young University Women
Sponsor: University of Seville
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
78.1%Beta blocker19.9%Metoprolol Succinate51%Carvedilol44%Metoprolol Tartrate5%Part D<11 patientsStatin13.3%Atorvastatin Calcium71%Rosuvastatin Calcium29%Part D≥39 patients+ 10 more classes in this area
Metabolism & gastrointestinal
10.8%SGLT2 inhibitor10%Jardiance55%Farxiga45%Part D≥20 patientsProton pump inhibitor0.9%Pantoprazole Sodium100%Part D<11 patientsBlood & clotting
7.3%Factor Xa inhibitor7.3%Eliquis82%Xarelto19%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
- CD40 Immunotherapy Effect on the Cardiac Immune Landscape and Response to Myocardial Disease
Washington University
FY2026$162,705K08HL163518 - CD40 Immunotherapy Effect on the Cardiac Immune Landscape and Response to Myocardial Disease
Washington University
FY2025$162,935K08HL163518 - CD40 Immunotherapy Effect on the Cardiac Immune Landscape and Response to Myocardial Disease
Washington University
FY2024$163,255K08HL163518
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”